drugset / Trial / NCT00362635

Compare the Efficacy and Safety of 48-week Treatment With Clevudine 30mg Versus Lamivudine 100mg for CHB Infection

NCT00362635

Phase 3 Completed 92 enrolled Bukwang Pharmaceutical
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to compare the efficacy and safety of 48-week treatment with Clevudine 30 mg qd versus lamivudine 100 mg qd for chronic hepatitis B infection.

Timeline

Start
2006-08
Primary completion
2011-12
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Clevudine Small molecule 30 mg